Seer reported third-quarter revenue of
“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform,” said
Recent Business and Corporate Highlights
- Established customers continued to purchase consumables, including accounts with purchases across multiple consecutive quarters. Several new large pharmaceutical customers purchased instruments and consumables this year, supporting opportunities for larger studies and broader use within customer accounts.
- Announced on
October 29 that the Special Committee of Seer’s Board of Directors completed its review and Seer will remain an independent public company, reinforcing the Company’s continued commitment to innovation, service and customer support. - Announced on
November 5 that, following Nanomics Biotechnology Co., Ltd.’s withdrawal from defending theU.S. International Trade Commission (“ITC”) investigation brought by Seer and Brigham and Women’s Hospital, the ITC’s investigative staff recommended granting the full exclusion and cease-and-desist orders requested. The Commission’s final determination remains pending and is expected by year-end.
Scientific Highlights
- Publications, preprints and reviews describing research conducted using Proteograph reached 116, up from 95 at the last quarterly update, highlighting the discoveries researchers are advancing across a broad range of applications.
- PRECISE-SG100K investigators presented preliminary findings at HUPO 2026 from 9,658 plasma samples. Using Proteograph with Thermo Fisher’s Orbitrap Astral mass spectrometer, they quantified approximately 8,800 protein groups across the study and 88,000 peptides per sample.
- Proteograph’s nanoparticle enrichment substantially expands the plasma proteome available for discovery. Published studies and customer presentations using matched plasma samples have repeatedly shown that conventional mass spectrometry workflows without Proteograph achieve approximately 10–15% of the protein coverage achieved with Proteograph. The Proteograph makes thousands of additional proteins accessible for biological investigation.
- PRECISE investigators identified more than 4,200 proteins with significant associations between nearby genetic variation and protein abundance, or cis-pQTLs. They reported 2,762 genetic–protein associations not previously reported across 12 reference studies and linked proteins to 71 health-related traits, illustrating the discovery potential of deep proteomics at population scale.
- In an independent study published in Clinical Proteomics,
CHA University researchers compared seven plasma preparation approaches. Proteograph XT delivered the greatest coverage, averaging approximately 6,060 proteins per sample, and the lowest rate of missing protein measurements, at 1.9%. - Korea University Professors
Sang-Won Lee andJaewoo Kang presented preliminary findings from more than 5,500 plasma samples at ASMS and HUPO 2026. Their ID-Free AI Proteomics approach used identified and unidentified spectral signals generated with Proteograph and mass spectrometry, improving overall cancer-classification performance compared with models using identified-peptide features alone.
Third Quarter 2026 Financial Results
Revenue was
Gross profit was
Operating expenses were
Net loss was
For the nine months ended
Cash, cash equivalents and investments were approximately
Capital Allocation
Through
Seer’s capital allocation approach combines investment in commercial adoption and product innovation with disciplined spending and share repurchases. Based on its current operating plan, the Company believes it has sufficient capital to reach cash flow breakeven.
2026 Guidance
Seer now expects full-year 2026 revenue to be in the range of
Webcast Information
Seer will host a conference call to discuss the third quarter 2026 financial results on
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at pr@seer.bio.
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s revenue guidance; the adoption and use of Seer’s products; expansion within customer accounts, sample volumes, repeat purchases and revenue growth; anticipated sample shipments under customer agreements; the potential applications of proteomic data in AI-driven research; capital allocation, share repurchases and the sufficiency of capital to reach cash flow breakeven under the current operating plan; and the enforcement of intellectual property rights, including the expected timing and outcome of the ITC proceeding. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Marissa Bych
investor@seer.bio
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue: | |||||||||||||||
| Product | $ | 2,760 | $ | 2,756 | $ | 7,193 | $ | 8,372 | |||||||
| Service | 1,064 | 913 | 2,283 | 2,913 | |||||||||||
| Related party | 90 | 300 | 146 | 761 | |||||||||||
| Other | 67 | 152 | 254 | 331 | |||||||||||
| Total revenue | 3,981 | 4,121 | 9,876 | 12,377 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Product | 1,411 | 1,327 | 3,817 | 3,868 | |||||||||||
| Service | 392 | 335 | 909 | 1,261 | |||||||||||
| Related party | 82 | 85 | 88 | 224 | |||||||||||
| Other | 217 | 264 | 695 | 742 | |||||||||||
| Total cost of revenue | 2,102 | 2,011 | 5,509 | 6,095 | |||||||||||
| Gross profit | 1,879 | 2,110 | 4,367 | 6,282 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 6,439 | 10,797 | 23,454 | 34,132 | |||||||||||
| Selling, general and administrative | 10,107 | 10,659 | 29,677 | 32,757 | |||||||||||
| Total operating expenses | 16,546 | 21,456 | 53,131 | 66,889 | |||||||||||
| Loss from operations | (14,667 | ) | (19,346 | ) | (48,764 | ) | (60,607 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Interest income | 1,961 | 2,765 | 6,238 | 8,974 | |||||||||||
| Loss on equity method investment | (1,392 | ) | (1,419 | ) | (5,208 | ) | (4,835 | ) | |||||||
| Other income (expense) | 365 | (210 | ) | 284 | (965 | ) | |||||||||
| Total other income | 934 | 1,136 | 1,314 | 3,174 | |||||||||||
| Loss before provision for income taxes | (13,733 | ) | (18,210 | ) | (47,450 | ) | (57,433 | ) | |||||||
| Provision for income taxes | 5 | 24 | 24 | 173 | |||||||||||
| Net loss | $ | (13,738 | ) | $ | (18,234 | ) | $ | (47,474 | ) | $ | (57,606 | ) | |||
| Other comprehensive loss: | |||||||||||||||
| Unrealized gain (loss) on available-for-sale securities | (410 | ) | 124 | (1,205 | ) | 295 | |||||||||
| Comprehensive loss | $ | (14,148 | ) | $ | (18,110 | ) | $ | (48,679 | ) | $ | (57,311 | ) | |||
| Net loss per share attributable to Class A and Class B common stockholders, basic and diluted | $ | (0.25 | ) | $ | (0.32 | ) | $ | (0.85 | ) | $ | (0.99 | ) | |||
| Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted | 55,562,071 | 56,312,290 | 55,572,439 | 57,928,898 | |||||||||||
Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) | ||||||||
2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 29,316 | $ | 47,285 | ||||
| Short-term investments | 126,581 | 138,612 | ||||||
| Accounts receivable, net | 2,717 | 4,282 | ||||||
| Related party receivables | 146 | 300 | ||||||
| Other receivables | 964 | 1,370 | ||||||
| Inventory | 6,396 | 7,795 | ||||||
| Prepaid expenses and other current assets | 1,777 | 1,890 | ||||||
| Total current assets | 167,897 | 201,534 | ||||||
| Long-term investments | 42,190 | 54,686 | ||||||
| Operating lease right-of-use assets | 18,663 | 20,488 | ||||||
| Property and equipment, net | 11,031 | 14,754 | ||||||
| Restricted cash | 524 | 524 | ||||||
| Other assets | 1,494 | 4,097 | ||||||
| Total assets | $ | 241,799 | $ | 296,083 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,583 | $ | 5,611 | ||||
| Accrued expenses | 4,070 | 7,135 | ||||||
| Deferred revenue | 482 | 341 | ||||||
| Operating lease liabilities, current | 2,786 | 2,575 | ||||||
| Other current liabilities | 21 | 29 | ||||||
| Total current liabilities | 9,942 | 15,691 | ||||||
| Operating lease liabilities, net of current portion | 18,956 | 21,077 | ||||||
| Other noncurrent liabilities | 10 | 8 | ||||||
| Total liabilities | 28,908 | 36,776 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Class A common stock, | 1 | 1 | ||||||
| Class B common stock, | — | — | ||||||
| Additional paid-in capital | 727,082 | 724,819 | ||||||
| Accumulated other comprehensive gain (loss) | (746 | ) | 459 | |||||
| Accumulated deficit | (513,446 | ) | (465,972 | ) | ||||
| Total stockholders’ equity | 212,891 | 259,307 | ||||||
| Total liabilities and stockholders’ equity | $ | 241,799 | $ | 296,083 | ||||
Source: